Event

Agenda

Innovative Therapies Days 2026

The 5th edition of the Innovative Therapies Days (ITD) will take place in Besanรงon (25), France, from the evening of October 8th, through October 8th and 9th. (www.innovativetherapiesdays.com)


This internationally recognized event is a must-attend for scientific and industrial professionals seeking to connect and accelerate the development of tomorrow’s treatments.


A Global Vision of Innovative Therapies Development

Innovative Therapies Days 2026 reinvents itself to expand its scope, covering the entire pipeline of innovative therapies, from fundamental research to the industrialization of products. Through a program structured around four thematic sessions, the event aims to foster fruitful exchanges between the scientific and industrial worlds. The goal is to accelerate the transition from scientific discoveries to tangible and effective treatments for patients.

A Unique Approach Focused on Clinical Results and Development Challenges

The conferences and presentations at this 2026 edition will highlight the potential of innovative therapies, as well as the clinical results achieved so far. They will also provide a detailed overview of the development process for each therapy: how they have evolved to their current stage, the obstacles encountered, and the solutions deployed to overcome them. This approach will give participants a better understanding of the crucial steps that transform a scientific discovery into a tangible and beneficial treatment for patients.


Why Participate?

Innovative Therapies Days 2026 is the perfect opportunity to strengthen collaborations between researchers, clinicians, industry professionals, and biotechnology companies. This event fosters exchanges, the identification of common solutions, and the creation of strategic partnerships to advance innovative therapies. Participants will also have the opportunity to discover major breakthroughs in fields such as gene and cell therapies, along with other innovations that are transforming the current medical landscape.


Register now and take advantage of special early registration offers!

Until June 15th, enjoy an exclusive Very Early Bird offer, and until July 30th, take advantage of the Early Bird offer! As a partner of this event, we offer you an additional 10% discount. Contact your representative now!


For more information, visit our website: www.innovativetherapiesdays.com
Linkedin: @Innovativetherapiesdays

MabDesign members benefit from 10% discount upon registration : Ask Us for the code

tรฉlรฉchargement
8-9 October 2026
Partner Event
Besanรงon (25), France.
ORGANIZER
PMT

Jean-Roch Fabreguettes

MEARY

Directeur Mรฉdical et Personne Responsable du Centre MEARY de thรฉrapie cellulaire et gรฉnique au sein de lโ€™hรดpital Saint-Louis ร  Paris

Jean-Roch Fabreguettes est un spรฉcialiste de la recherche translationnelle et des phases prรฉcoces de dรฉveloppement clinique des mรฉdicaments de thรฉrapie innovantes (MTI). Pharmacien, titulaire dโ€™un doctorat de lโ€™Universitรฉ de Montpellier 1, il a travaillรฉ plus de 25 ans dans le domaine et a contribuรฉ, pour des รฉquipes acadรฉmiques comme pour des start-ups, ร  la rรฉalisation de plus de 30 programmes de recherche sur diffรฉrents types de MTIย : thรฉrapie gรฉnique in vivo ou ex vivo, thรฉrapie cellulaire, ingรฉnierie tissulaire… Il est actuellement Directeur Mรฉdical et Personne Responsable du Centre MEARY de thรฉrapie cellulaire et gรฉnique au sein de lโ€™hรดpital Saint-Louis ร  Paris. Le centre MEARY est une plateforme de lโ€™Assistance Publique โ€“ Hรดpitaux de Paris (AP-HP), dรฉdiรฉe ร  la fabrication de mรฉdicament de thรฉrapie innovante expรฉrimentaux. Laboratoire membre de lโ€™ISCT, il est autorisรฉ par lโ€™ANSM et dispose dโ€™un certificat GMP. A ce titre Jean-Roch Fabreguettes est impliquรฉ dans le dรฉveloppement clinique et la fabrication de nombreux MTIย : CAR-T cells, lymphocytes T rรฉgulateurs, cellules stromales mรฉsenchymateusesโ€ฆ

Prรฉcรฉdemment, Jean-Roch Fabreguettes a รฉtรฉ expert Qualitรฉ (CMC) auprรจs de lโ€™ANSM durant 9 ans et a conseillรฉ diffรฉrentes sociรฉtรฉs de biotechnologies. Il est un intervenant rรฉgulier pour lโ€™Universitรฉ Paris Citรฉ et un membre actif de lโ€™ISCT et de rรฉseaux nationaux et internationaux sur les MTI (UNI-TC, Join4ATMP).